ID   PH61-N
AC   CVCL_D282
SY   PH61N
DR   BioSample; SAMN03151845
DR   BioSample; SAMN03472485
DR   cancercelllines; CVCL_D282
DR   CGH-DB; 181-1
DR   JCRB; JCRB1038
DR   Wikidata; Q54947352
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a MIA PaCa-2 derivative (PubMed=20143388).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00342.
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line).
CC   Discontinued: JCRB; JCRB1038; true.
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 12,13
ST   D16S539: 10,13
ST   D5S818: 12,13
ST   D7S820: 12,13
ST   TH01: 10
ST   TPOX: 9
ST   vWA: 15
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0428 ! MIA PaCa-2
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 23
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//